37Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Ireland
Neuroscience Intelligence
Ireland neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #37 of 50 · Data maturity A · Research score 30.9 · Data confidence 100.0 / 100 · Snapshot 2026-10-12 03:36 UTC.
10Recruiting trials
90Publications
40Institutions
Executive interpretation
Ireland ranks #37 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Merck Sharp & Dohme LLC104 recruiting
AbbVie20 recruiting
University College Dublin20 recruiting
Novo Nordisk A/S20 recruiting
FUJIFILM Toyama Chemical Co., Ltd.10 recruiting
Health Service Executive, Ireland11 recruiting
Amylyx Pharmaceuticals Inc.10 recruiting
Eli Lilly and Company10 recruiting
Massachusetts General Hospital10 recruiting
Heidelberg University11 recruiting
Disease activity
Parkinsons11trials
Alzheimers5trials
Epilepsy4trials
Stroke3trials
Other Neurology1trials
Schizophrenia1trials
Adhd1trials
Traumatic Brain Injury1trials
Als1trials
Autism1trials
Research institutions
Raidió Teilifís Éireann (Ireland)OpenAlexlinked institution
Mallinckrodt (Ireland)OpenAlexlinked institution
University College CorkOpenAlexlinked institution
APC Microbiome InstituteOpenAlexlinked institution
University Hospital GalwayOpenAlexlinked institution
National Maternity HospitalOpenAlexlinked institution
Royal College of Surgeons in IrelandOpenAlexlinked institution
University of LimerickOpenAlexlinked institution
Insight SFI Research Centre for Data AnalyticsOpenAlexlinked institution
Children's Health Ireland at CrumlinOpenAlexlinked institution
Clinical evidence trail
NCT07798674TreatHSP Platform: Adaptive Natural History Platform for Ataxias, HSPs, and Spastic AtaxiasRECRUITING
NCT07106632Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic TestsRECRUITING
NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)RECRUITING
NCT06563895Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantRECRUITING
NCT05269394Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)ACTIVE_NOT_RECRUITING
NCT05239728A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)ACTIVE_NOT_RECRUITING
NCT05064878A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.ACTIVE_NOT_RECRUITING
NCT04736706A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)ACTIVE_NOT_RECRUITING
NCT03765918Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)ACTIVE_NOT_RECRUITING
NCT05906043A Multidisciplinary Approach to Assessing and Treating Fatigue in Inflammatory Bowel DiseaseUNKNOWN
Research evidence trail
PUBMEDPersonalized whole-body modeling links gut microbiota to metabolic perturbations in Alzheimer's disease.2026-12-31
PUBMEDUnravelling the role of the gut microbiome in antipsychotic-induced weight gain and metabolic dysfunction in humans and rodents: A systematic review.2026-12-01
PUBMEDSyndemic Pattern of Sexualized Drug Use and Mental Distress Among Trans Women/Khawaja Siras in Pakistan: Results From a Multicentric Latent Class Analysis.2026-10-08
PUBMEDThe Influence of Symptoms and Psychosocial Factors on Quality of Life and Life Satisfaction in Parkinson's Disease.2026-10-06
PUBMEDColchicine for Secondary Prevention After Stroke According to the Presence of Atherosclerosis.2026-10-01
PUBMEDAge-dependent reorganization of behavioral and striatal function in Cntnap2 knockout mice.2026-10-01
PUBMEDDelivery of CDNF in collagen hydrogels modulates N-glycosylation while improving motor function in a rodent model of Parkinson's disease.2026-10-01
PUBMEDA qualitative exploration of the lived experience of decompressive craniectomy among acquired brain injury survivors.2026-09-10
PUBMEDRemodeling of the glutamatergic system in the Alzheimer's disease medial temporal lobe and superior temporal gyrus.2026-09-01
PUBMEDRapid Resolution of Apophenic Psychosis With Low-Dose Olanzapine in Very Late-Onset Schizophrenia-Like Psychosis.2026-09-01
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.